

ZENBEXUS (IBERDOMIDE) PATIENT CARD

This document has been reviewed and approved by the Saudi Food and Drug Authority (SFDA).



Patient instructions: Carry this card with you at all times. Tell any healthcare professional who sees you that you are taking iberdomide.

Health Authority Approval Date: September 2026

Local approval number: 2070-SA-2600002



SAFETY INFORMATION FOR PATIENTS WHO CAN BECOME PREGNANT

- Iberdomide may cause harm to an unborn baby if used during pregnancy.
 - Iberdomide must not be taken if you are pregnant, and you must not become pregnant while taking iberdomide.
 - Talk to your doctor if you are pregnant, suspect you may be pregnant, or are planning to become pregnant.
-
- Inform the doctor prescribing your contraception about the iberdomide treatment.
 - Inform the doctor prescribing you iberdomide if you have changed or stopped contraception.
 - If you can get pregnant, you must always use effective contraception before, during, and for at least 4 weeks after your last dose.
-
- You must also obtain a medically supervised negative pregnancy test before, during, and for at least 4 weeks after your last dose.
 - If you suspect that you may be pregnant, you must inform your doctor and STOP taking iberdomide immediately.
 - You must tell your doctor immediately if you experience any symptom of pregnancy.
 - It is not known whether iberdomide is excreted in breast milk. Therefore, breast-feeding should be discontinued during therapy with iberdomide.



EMERGENCY CONTACT INFORMATION

Name of patient: _____

Emergency prescriber contact: _____

Telephone number during office hours:

Telephone number after office hours:



Further information is available in the Patient Information Leaflet (PIL) and Guide for Risk Minimization for Patients.

For further information or for reporting any suspected adverse reactions via the national reporting system :
Bristol Myers Squibb, Saudi Arabia :
At email: medinfo.SaudiArabia@bms.com
or call: 800 844 7710

The National Pharmacovigilance Centre (NPC)
Saudi Food and Drug Authority (SFDA):
SFDA call center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: <https://ade.sfda.gov.sa>



© 2026

Bristol-Myers Squibb Company.

Date of Health Authority Approval: September 2026

Local Approval Number: 2070-SA-2600002